SCHEMBL22769711

SCHEMBL22769711

COc1cc2nccc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3)c2c2c1OCCO2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.64
MET P08581 5/20 0.48
KDR P35968 9/20 0.47
AXL P30530 5/20 0.47
MERTK Q12866 2/20 0.47
AURKA O14965 1/20 0.47
RIPK2 O43353 1/20 0.47
ABCB11 O95342 1/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
ERBB2 P04626 1/20 0.47
NTRK1 P04629 1/20 0.47
LCK P06239 1/20 0.47
PGR P06401 1/20 0.47
LYN P07948 1/20 0.47
CHRM2 P08172 1/20 0.47
HCK P08631 1/20 0.47
ADRA2A P08913 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
KIT P10721 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30278578 0.92 RET (0.57) RETMETKDRAXLMERTK
SCHEMBL22769735 0.92 RET (0.57) RETMETKDRAXLMERTK
SCHEMBL22769734 0.91 RET (0.56) RETMETKDRAXLMERTK
SCHEMBL21246969 0.86 RET (0.50) RETMETKDRAXLMERTK
SCHEMBL22769737 0.85 KDR (0.64) RETMETKDRAXLMERTK
SCHEMBL372017 0.84 MET (0.66) RETMETKDRAXLMERTK
SCHEMBL29883010 0.84 MET (0.66) RETMETKDRAXLMERTK
SCHEMBL22769702 0.84 MET (0.57) RETMETKDRAXLMERTK
SCHEMBL22769724 0.83 MET (0.55) RETMETKDRAXLMERTK
SCHEMBL22769718 0.83 MET (0.55) RETMETKDRAXLEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3750893-B1 DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-04-19 EP disclosed
US-11407760-B2 Dioxinoquinoline compounds, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2022-08-09 US disclosed
US-20200399285-A1 DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2020-12-24 US disclosed
EP-3750893-A1 DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2020-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407760-B2 Dioxinoquinoline compounds, preparation method and uses thereof KDR, MET, ABL1 RET 7/4885MET 2/4885KDR 1/4885
US-20200399285-A1 DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF KDR, MET, ABL1 RET 7/4885MET 2/4885KDR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.